Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019

作     者：Meng-Yuan Liu Bo Zheng Yan Zhang Jian-Ping Li Liu Meng-Yuan;Zheng Bo;Zhang Yan;Li Jian-Ping

作者机构：Department of CardiologyPeking University First HospitalBeijing 100034China NHC Key Laboratory'of Cardiovascular Molecular Biology and Regulatory PeptidesBeijing 100034China Key Laboratory of Molecular Cardiovascular Sciences of Ministry of EducationHealth Science CenterPeking UniversityBeijing 100034China 

出 版 物：《Chronic Diseases and Translational Medicine》 (慢性疾病与转化医学（英文版）)

年 卷 期：2020年第6卷第2期

页      面：98-105页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

主　　题：Severe acute respiratory syndrome coronavirus 2 Angiotensin-converting enzyme 2 Acute lung injury 

摘      要：Coronavirus disease 2019 is a major threat to public health globally.Though its pathogenesis has not been fully elucidated,angiotensin-converting enzyme 2(ACE2)has been recently identified as a receptor for the entry of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)into the cell.Here,we aimed to clarify the potential role of ACE2 in SARS-CoV-2-induced acute lung injury and its underlying mechanism.As a receptor for coronavirus,ACE2 mediates the entry of SARS-CoV-2 into cells in a similar way as for severe acute respiratory syndrome coronavirus(SARS-CoV).The high binding affinity of SARS-CoV-2 to ACE2 correlates with its efficient spread among humans.On the other hand,ACE2 negatively regulates the renin-angiotensinaldosterone system(RAAS)primarily by converting angiotensinⅡto angiotensin 1-7.which exerts a beneficial effect on coronavirus-induced acute lung injury.Human recombinant ACE2 has been considered as a potential therapy for SARS-CoV-2 by blocking virus entry and redressing the imbalance of RAAS in SARS-CoV-2 infection.The level of ACE2 expression can be upregulated by treatment with an ACE inhibitor(ACEI)or angiotensinⅡtype 1 receptor blocker(ARB).To date,no evidence shows that ACEIs or ARBs increase the susceptibility and mortality of patients infected with SARS-CoV-2,and hence,it is not advisable to discontinue such drugs in patients with cardiovascular disease.